Document Detail


Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
MedLine Citation:
PMID:  15679764     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Rebound acid hypersecretion develops after the use of acid inhibitors. AIM: To estimate the duration of hypersecretion and to elucidate the role of the enterochromaffin-like (ECL) cell in rebound acid hypersecretion. METHODS: Patients waiting for anti-reflux surgery who had used a proton pump inhibitor daily > 1 year were included. All patients discontinued taking acid inhibiting drugs after the operation. Basal and pentagastrin stimulated acid output was measured at 4, 8, 16 and 26 weeks postoperatively. Oxyntic mucosal biopsies were collected before and 26 weeks after the operation for counting of histidine decarboxylase (HDC) immunoreactive cells. Serum chromogranin A (CgA) and gastrin were measured before and at 4, 8, 16 and 26 weeks after the operation. RESULTS: Pentagastrin stimulated acid secretion was higher at 4 and 8 weeks than at 26 weeks after the operation. Gastrin and CgA were significantly reduced at 4 and 8 weeks, respectively. The number of HDC immunoreactive cells was reduced by 60% at 26 weeks postoperative. DISCUSSION: Rebound acid hypersecretion lasts more than 8 weeks, but less than 26 weeks after long-term proton pump inhibition. CONCLUSION: The findings indicate that not only the parietal cell mass, but also ECL cell mass and activity are involved in the mechanism of acid hypersecretion.
Authors:
R Fossmark; G Johnsen; E Johanessen; H L Waldum
Related Documents :
10223764 - Effect of restorative proctocolectomy on gastric acid secretion and serum gastrin level...
11514234 - Conjugated linoleic acid isomers have differential effects on triglyceride secretion in...
1361914 - Effects of drugs acting on cl(-)-hco3- and na(+)-h+ exchangers on acid secretion in the...
7137354 - Nutrient and bowel segment dependency of human intestinal control of gastric secretion.
23173174 - Functional characterization of the chicken fatty acid elongases.
3080004 - Marked and prolonged inhibition of mammalian ornithine decarboxylase in vivo by esters ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  21     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2005 Jan 
Date Detail:
Created Date:  2005-01-31     Completed Date:  2005-09-30     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  149-54     Citation Subset:  IM    
Affiliation:
Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway. reidar.fossmark@medisin.ntnu.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
2-Pyridinylmethylsulfinylbenzimidazoles
Adult
Aged
Antacids / therapeutic use*
Anti-Ulcer Agents / therapeutic use
Enterochromaffin-like Cells / metabolism*
Esophagitis / drug therapy,  metabolism
Female
Gastric Acid / secretion*
Gastroesophageal Reflux / drug therapy*,  metabolism
Humans
Immunohistochemistry
Long-Term Care
Male
Middle Aged
Omeprazole / analogs & derivatives,  therapeutic use
Pentagastrin / pharmacology
Proton Pumps / antagonists & inhibitors
Chemical
Reg. No./Substance:
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Antacids; 0/Anti-Ulcer Agents; 0/Proton Pumps; 103577-45-3/lansoprazole; 5534-95-2/Pentagastrin; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Functional symptoms in inflammatory bowel disease and their potential influence in misclassification...
Next Document:  Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditi...